NEW YORK, September 29, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG),
Halozyme Therapeutics, Inc. (NASDAQ: HALO), Amarin
Corporation PLC (NASDAQ: AMRN), Epizyme, Inc. (NASDAQ:
EPZM), EXACT Sciences Corporation (NASDAQ: EXAS). On
Monday, September 28, 2015, Nasdaq
ended at 4543.97, down 3.04%, Dow Jones declined 1.92%, to finish
the day at 16001.89, and the S&P closed at 1881.77, down 2.57%.
Register for your complimentary reports at the links given below.
--
AMAG Pharmaceuticals Inc
--
AMAG Pharmaceuticals Inc's stock edged lower by 8.85% to close
Monday's session at USD 39.86. The
company's shares oscillated between USD
38.51 and USD 44.48. The stock recorded a trading volume of
2.06 million shares, which was above its 50-day daily average
volume of 1.12 million shares and above its 52-week average volume
of 0.80 million shares. Over the last three days, AMAG
Pharmaceuticals Inc's shares have declined by 12.63% and in the
past one week it has moved down 13.25%. Furthermore, over the last
three months, the stock has lost 40.63% and in the past six months,
the shares have shed 29.05%. Further, the company is trading at a
price to earnings ratio of 6.71 and a price to book ratio of 1.73.
This compares to a historical PE ratio of 7.92. The historical PB
ratio is near to 2.37. Additionally, the stock is trading at a
price to cash flow ratio of 10.87 and price to sales ratio of 4.64.
Sign up and read the free notes on AMAG at:
http://www.aciassociation.com/AMAG.pdf
--
Halozyme Therapeutics Inc
--
The stock of Halozyme Therapeutics Inc lost 9.49% to close
Monday's session at USD 14.50. The
shares of the company moved in the range of USD 14.25 and USD
15.90. A trading volume of 1.97 million shares was recorded,
which was greater than its 150-day daily average volume of 1.41
million shares and above its 52-week average volume of 1.49 million
shares. Over the last five days, Halozyme Therapeutics Inc's shares
have declined by 20.42% and in the past one month, it has lost
16.95%. However, the stock has returned 21.24% in the past one
month, and 31.41% in the last three months, on a compounded total
return basis. The stock is at a price to book ratio of 36.88. The
historical PB ratio is near to 29.34. Further, the stock is trading
at a price to sales ratio of 17.31. Register for free on ACI
Association and access the latest research on HALO at:
http://www.aciassociation.com/HALO.pdf
--
AMARIN CORPORATION
PLC
--
AMARIN CORPORATION PLC's stock decreased by 7.27% to close
Monday's session at USD 2.04. The
company's shares fluctuated in the range of USD 1.99 and USD
2.16. A total of 1.97 million shares exchanged hands, which
surpassed its 50-day daily average volume of 1.67 million shares
and was below its 52-week average volume of 2.66 million shares.
Over the last three days AMARIN CORPORATION PLC's shares have
declined by 10.92% and in the past one week it has moved down
12.82%. Furthermore, over the last three months, the stock has lost
11.69% and in the past six months, the shares have shed 14.64%. The
complete research on AMRN is available for free at:
http://www.aciassociation.com/AMRN.pdf
--
Epizyme Inc
--
Epizyme Inc's stock slipped by 27.22% to close Monday's session
at USD 13.02. The company's shares
oscillated between USD 12.00 and USD
17.99 marking a new 52-week low during the session. The
stock recorded a trading volume of 1.97 million shares, which was
above its 50-day daily average volume of 0.45 million shares and
above its 52-week average volume of 0.41 million shares. Over the
last five days, Epizyme Inc's shares have declined by 31.97% and in
the past one month, it has lost 25.68%. In addition, over the last
three months, the stock has lost 36.39% and year to date, the
shares have shed 31.00%. Free in-depth research on EPZM is
available at:
http://www.aciassociation.com/EPZM.pdf
--
Exact Sciences Corp
--
Exact Sciences Corp's stock declined 3.60% to close Monday's
session at USD 18.22. The share price
vacillated between USD 18.02 and USD
19.41. The stock recorded a trading volume of 1.97 million
shares, which was above its 50-day daily average volume of 1.41
million shares and above its 52-week average volume of 1.65 million
shares. Over the last three days Exact Sciences Corp's shares have
declined by 5.05% and in the past one week it has moved down 1.67%.
Moreover, in the last six months, the stock has lost 20.89% and
year to date, the shares have shed 33.60%. The stock is at a price
to book ratio of 7.22. The historical PB ratio is near to 8.42.
Additionally, the stock is trading at a price to sales ratio of
126.05. The complimentary notes on EXAS can be downloaded in PDF
format at: http://www.aciassociation.com/EXAS.pdf
--
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been
sourced from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com